A Research Study in Saudi Arabia to Understand How the Dose Check App Used With Tresiba Treatment Helps to Control Blood Sugar Level

Sponsor
Novo Nordisk A/S
Study ID
NCT06153537
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Insulin degludec — DRUG
    Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.

Study Details

This study looks at how a mobile based app called 'Dose Check' used along with Tresiba helps to control blood sugar level in participants with type 2 diabetes mellitus. Participants will get Tresiba as prescribed by the study doctor or participants will continue already prescribed treatment with Tresiba. Participants will also be prescribed to use Dose Check app by the study doctor and will be asked to install the Dose Check app in their mobile phone, which will support participants with the correct dose of Tresiba. This study will last for about 6 to 7 months.

Key Dates

Start date
Nov 29, 2023
Status verified
Jan 2026
Primary completion
Mar 24, 2025
Completion
Mar 24, 2025

Study Design

Enrollment
179 participants (actual)

Arms

  • Arm: Insulin degludec + dose check
    Participants will be treated with commercially available insulin degludec used with Dose Check app according to local label and routine clinical practice at the discretion of the treating physician.

Primary Outcome Measure

Change in glycated haemoglobin (HbA1c) [ Time Frame: From baseline (week 0) to end of study visit(week 26 [-4 to +8 weeks]) ]

Related Studies